Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts have updated their price targets and ratings for several US-listed companies, including upgrades and downgrades. Notable mentions include Urban Outfitters, United Therapeutics, Mohawk Industries, NerdWallet, Teva Pharmaceutical, Assurant, Viavi Solutions, Rivian Automotive, Construction Partners, and XPO, Inc. These changes reflect analysts' revised expectations based on various factors likely affecting each company's stock performance.
February 12, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Deutsche Bank upgraded Mohawk Industries from Hold to Buy and raised the price target from $98 to $152. Shares gained 0.4% to close at $110.01.
The upgrade to Buy and significant price target increase by Deutsche Bank suggest a strong positive outlook for Mohawk Industries, likely leading to short-term stock appreciation.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Keybanc maintained an Overweight rating on NerdWallet and raised the price target from $18 to $20. Shares rose 2% to close at $15.52.
The maintained Overweight rating and increased price target by Keybanc indicate continued confidence in NerdWallet, supporting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90
POSITIVE IMPACT
Piper Sandler upgraded Teva Pharmaceutical from Neutral to Overweight and raised the price target from $12 to $19. Shares fell 0.7% to close at $12.01.
The upgrade to Overweight and significant price target increase by Piper Sandler suggest a bullish outlook for Teva Pharmaceutical, potentially leading to short-term stock appreciation despite the recent dip.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
UBS upgraded Urban Outfitters from Sell to Neutral and raised the price target from $21 to $41. Shares gained 2.2% to close at $42.53.
The upgrade and significant price target increase by UBS suggest a positive outlook for Urban Outfitters, potentially leading to short-term stock appreciation.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Goldman Sachs upgraded United Therapeutics from Sell to Neutral and raised the price target from $213 to $215. Shares rose 0.3% to close at $212.34.
The upgrade and modest price target increase by Goldman Sachs indicate a slightly improved outlook for United Therapeutics, which could support its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90